Etiotropic therapy of COVID-19 disease in the work of nursing staff

Abstract

The novel coronavirus infection, or COVID-19 (from «Coronavirus disease 2019»), is a new epidemic infectious disease that poses a danger to the population due to its high contagiousness and the development of life-threatening complications for the patient, such as respiratory and multiple organ failure. In 2021, it became clear that the reasonable use of antiviral therapy drugs is necessary for a favorable outcome of the disease. The review considers the main antiviral drugs proposed by the WHO for the treatment of the novel coronavirus infection (COVID-19). They are based on studies with statistically significant data that allow fully assessing their effectiveness and make it possible to make an adequate decision on the prescription of these drugs. Based on the data obtained from in vitro studies and clinical trials, the paper considers the prospects of using these drugs in the treatment of the novel coronavirus infection, their effectiveness in clinical practice, as well as the feasibility of their use and possible combinations for prescribing these drugs that can be used to treat and prevent the novel coronavirus infection. The article discusses the efficacy of the following drugs: remdesivir, interferon, lopinavir and ritonavir, umifenovir, darunavir and cobicistat, favipiravir, chloroquine and hydroxychloroquine, ivermectin and intravenous immunoglobulins.